论文部分内容阅读
目的探究DACH2在肌层浸润性膀胱尿路上皮癌(UCB)中的表达及对预后判断的临床意义。方法通过免疫组化、Western Blot和RT-PCR技术检测伴淋巴结转移和不伴淋巴结转移的肌层浸润性UCB患者术后标本中的DACH2的表达情况,分析DACH2的表达及与患者预后之间的关系,验证DACH2能否作为独立预测肌层浸润性UCB预后的分子标记物。结果免疫组化、Western Blot和RT-PCR结果一致显示,DACH2在伴淋巴结转移的肌层浸润性UCB标本中有较高表达,且差异均有统计学意义(P<0.05)。DACH2表达与肿瘤高分级相关,差异有统计学意义(P<0.05),DACH2表达与患者无转移生存率和总生存率相关,差异有统计学意义(P<0.05)。结论 DACH2可作为一个有潜力的分子标记物指导肌层浸润性UCB预后的判断。
Objective To investigate the expression of DACH2 in invasive bladder urothelial carcinoma (UCB) and its clinical significance. Methods Immunohistochemistry, Western Blot and RT-PCR were used to detect the expression of DACH2 in myometrial invasive UCB patients with lymph node metastasis and non-lymph node metastasis. The expression of DACH2 and the prognosis of patients with UCB Relationship to verify whether DACH2 could be used as a molecular marker to independently predict the prognosis of myometrial invasive UCB. Results The results of immunohistochemistry, Western Blot and RT-PCR showed that DACH2 was highly expressed in myometrial invasive UCB specimens with lymph node metastasis, and the difference was statistically significant (P <0.05). DACH2 expression was correlated with tumor grade (P <0.05). The expression of DACH2 was correlated with the non-metastatic survival rate and overall survival rate (P <0.05). Conclusion DACH2 can be used as a potential molecular marker to judge the prognosis of myometrial invasive UCB.